ReviewMolecular therapy. Oncology2026
Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision.
Review in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas, particularly glioblastoma (GBM), remain highly lethal brain tumors with limited treatments. MRI-based monitoring lacks specificity in distinguishing progression from treatment effects. Circulating microRNAs (miRNAs), small non-coding RNAs involved in tumor biology, show promise as liquid biopsy biomarkers. We searched PubMed, Embase, Scopus, and Web of Science for clinical studies investigating circulating miRNAs as diagnostic, prognostic, or predictive biomarkers in glioma, across plasma, serum, and cerebrospinal fluid (CSF). Oncogenic miRNAs (oncomiRs) such as miR-21, miR-10b, miR-182, and miR-210 were consistently upregulated in glioma patients, whereas tumor suppressors including miR-124, miR-128, miR-137, and miR-181 family members were downregulated. Prognostically, elevated miR-21, miR-222, and miR-196b correlated with poor survival, while reduced miR-181d, miR-100, and miR-145 predicted worse outcomes. Composite signatures, particularly exosomal or CSF-derived panels, outperformed single markers. Dynamic changes in miR-21, miR-222, and miR-210 reflected treatment response or progression, with exosomal miR-1238 emerging as a marker of temozolomide resistance. Longitudinal serum levels of miR-223 and miR-320e correlated with MRI tumor volume and distinguished true progression from pseudo-progression. Circulating miRNAs show strong potential as minimally invasive biomarkers for glioma management, but clinical translation remains limited by technical and biological variability and lack of validation. Advances in biosensors, multi-omics, and standardization are key to clinical integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.